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Multipotent hematopoietic stem cells (HSCs) sustain blood cell production throughout an individual’s lifespan through complex
processes ultimately leading to fates of self-renewal, diﬀerentiation or cell death decisions. A ﬁne balance between these decisions
in vivo allows for the size of the HSC pool to be maintained. While many key factors involved in regulating HSC/progenitor cell
diﬀerentiation and cell death are known, the critical regulators of HSC self-renewal are largely unknown. In recent years, however,
a number of studies describing methods of increasing or decreasing the numbers of HSCs in a given population have emerged. Of
major interest here are the emerging roles of retinoids in the regulation of HSCs.
Copyright © 2007 Louise E. Purton. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
1.1. CellfatedecisionsofHSCs
HSCs maintain hematopoiesis through ﬁne processes in-
volving cell self-renewal, diﬀerentiation, or death decisions
(Figure 1). A balance between these choices is required for
homeostasis of the blood cell system. Imbalances can result
in severe consequences to the health of the individual: bone
marrow failure can result from reduced HSC self-renewal or
enhanced cell diﬀerentiation or death, whereas bone marrow
diseasessuchasleukemialargelyresultfrominhibitionofcell
diﬀerentiation or death of a progenitor cell in addition to en-
hanced self-renewal of the leukemia-initiating cell.
1.2. Functionalself-renewalofHSCs
HSC self-renewal is deﬁned in this review as the retention of
the functional capacity of the HSC after cell division. Stud-
ies investigating the regulation of HSC self-renewal have pre-
dominantly focused on ex vivo culture systems, which, while
allowing more direct examination of the roles of certain fac-
tors in the absence of others, may not provide informa-
tion as to physiological regulators of HSC self-renewal, es-
pecially with regards to microenvironmental inﬂuences. The
importance of the bone marrow microenvironment in reg-
ulating hematopoiesis has been demonstrated by the capac-
ity of in vitro bone marrow stromal cell cultures to support
hematopoietic stem cells [1] . To date, however, both in vitro
and in vivo studies of the microenvironmental regulators of
HSC self-renewal have been relatively few. This is due in part
to the complexity of the multicellular stromal cell system in
addition to the lack of identiﬁcation of the HSC-regulatory
cells within the stromal cell compartment, also known as the
HSC niche. The recent identiﬁcation that a key component
of the in vivo HSC niche is the osteoblast, or bone-forming
cells [2,3],inadditiontotheobservationthatachangeinthe
osteoblastnichesizehasamarkedimpactontheabilityofthe
HSCs to self-renew, has now opened the ﬁeld for further in-
vestigation in the context of the microenvironmental regula-
tionofHSCself-renewal.Thestudiesreportedherehavepre-
dominantly been performed independent of the HSC niche,
thus represent intrinsic, or cell-autonomous, roles in HSC
function.
1.3. Retinoids
Vitamin A (retinol) and its derivatives, collectively referred
to as retinoids, are essential for normal development and2 PPAR Research
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Figure 1: Hematopoietic stem cells (HSCs) undergo fate decisions
including self-renewal (resulting in the production of more HSCs),
diﬀerentiation (producing more mature progenitor cells), senes-
cence, or apoptosis, the latter two resulting in cell death.
homeostasisofvertebratesasshownbytheirprofound eﬀects
as morphogens during embryonic development [4]a n db y
their crucial role in the physiology of many organs. The
mechanisms responsible for the diverse eﬀects of retinoids
have yet to be fully elucidated but are ultimately dependent
on the speciﬁc binding of retinoid ligands to nuclear recep-
tors, which as ligand-dependent transcription factors regu-
late complex programs of gene expression in various target
cells and tissues.
Retinol is not synthesized by animals, but is obtained
from a variety of food sources in the form of carotenoids
(from fruits and vegetables) or retinyl esters (from animal
sources, especially liver). Retinol is a teratogenic agent: vi-
tamin A deﬁciency results in multiple and severe develop-
mental defects in many diﬀerent organs. Paradoxically, ex-
cess retinol (hypervitaminosis A) causes many serious devel-
opmental defects. These ﬁndings not only highlight the im-
portance of retinoids in regulating many developmental pro-
cesses, but they also emphasize how critical it is to regulate
retinoid levels within the body [5, 6].
Retinol is not biologically active, but is metabolized
within the body by a series of enzymes into a range of bi-
ologically active forms of aldehyde or carboxylic acids [7].
The major aldehyde form, 11-cis retinal, is crucial for nor-
mal processes involved in vision. The major carboxylic acid
form, all-transretinoic acid (ATRA), is required for the regu-
lation of gene transcription by vitamin A [7], and is the form
of vitamin A that has roles in hematopoiesis.
1.4. Retinoicacidreceptors
The biologic eﬀects of ATRA and other retinoids are me-
diated by two families of receptors belonging to the nu-
clear hormone receptor superfamily: the retinoic acid re-
ceptor (RAR) and retinoid X receptor (RXR) families [8].
These receptors are encoded by a number of related genes,
each of which generates distinct subtypes (designated α, β,
and γ), and each subtype has at least 2 diﬀerent isoforms
generated by alternative splicing [9, 10]. The retinoid recep-
tors are highly conserved between species and show complex
stage- and tissue-speciﬁc patterns of expression, suggesting a
molecular basis for the diverse biological eﬀects of retinoids.
RAR/RXR heterodimers are the functional units responsi-
ble for the transduction of retinoid signals [11], binding to
speciﬁc retinoic acid response elements (RAREs) present in
the promoters of their target genes to regulate transcription
[8]. The retinoid receptors have two contrasting roles in the
regulation of transcription. When not bound to ligand, the
RAR/RXR heterodimers repress transcription. In contrast,
in the liganded state, these receptors activate transcription.
ATRA preferentially binds to RARs but not RXRs. RARs are
speciﬁc to the retinoid signalling pathway, whereas RXRs
also heterodimerize with other members of the nuclear hor-
monereceptorsuperfamily.Thereareveryfewreportsonthe
roles of the RXRs in hematopoiesis, however, a recent report
showedthatmicelackingRXRα,whichiswidelyexpressedby
hematopoietic cells, have normal hematopoiesis in vivo [12].
1.5. Theeffectsofretinoidsonhematopoiesis
In hematopoiesis, the best documented action of retinoids is
the induction of diﬀerentiation of primary leukemic blasts
from patients with acute promyelocytic leukemia (APML),
andtherapiesthatincludeATRAtreatmentachievesustained
remission in approximately 75% of patients [13].
Numerous studies investigating the eﬀects of ATRA on
normal human and murine hematopoiesis reached variable
and often contrasting conclusions. Some reports suggested
that ATRA enhanced the proliferation of human progenitor
cells [14–16], whereas others demonstrated an inhibitory ef-
fect on both proliferation and diﬀerentiation of both human
and murine progenitor cells [17–21]. It must be noted that
inhibition of proliferation could be interpreted in diﬀerent
ways depending on the cell type: inhibition of proliferation
in maturing cells is associated with cell cycle arrest accom-
panied by diﬀerentiation of the cell, as observed when im-
mature granulocytes diﬀerentiate in response to ATRA [22].
In contrast, in the context of immature hematopoietic cells,
especially HSCs, which are relatively quiescent cells [23], in-
hibition of proliferation (or more appropriately, slowing of
proliferation)maybeassociatedwithmaintenanceofaprim-
itive state of the cell. This has been observed when immature
hematopoietic cells enriched for HSCs were cultured with
ATRA [18, 24, 25].
Indeed, these contradictory eﬀects of ATRA in
hematopoiesis may be resolved by the recent ﬁnding
that ATRA has pleiotropic eﬀects on murine hematopoietic
cells. In accord with its eﬀects in APML, ATRA was found
to be a potent inducer of terminal maturation of normal
promyelocytes into granulocytes [24]. However, on more
immature populations of hematopoietic cells enriched in
hematopoietic stem and progenitor cells (lineage-negative,
c-kit -positive, Sca-1-positive cells [LKS+]) [26], ATRA
exhibited the opposite eﬀect. The addition of ATRA to ex
vivo liquid suspension media containing cytokines markedly
prolonged and enhanced the production of colony-formingLouise E. Purton 3
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Figure 2: A summary of the eﬀects of ATRA on HSC-containing
LKS+ cells. LTRC= long-term repopulating HSCs, STRC = short-
term repopulating HSCs, CFU-S = colony-forming unit-spleen,
CFC = colony-forming cell. Upward pointing arrows indicate in-
creaseinpotential,thenumberofarrowsindicatesthemagnitudeof
increase, sideways arrows indicate maintenance of potential. Modi-
ﬁed from [25].
cells (CFCs) and colony-forming unit-spleen (CFU-S) and
maintained pre-CFU-S production from cultured LKS+
[24, 25]. In addition, ATRA enhanced the maintenance of in
vivo repopulating HSCs from this cultured cell population
[25]. Additional studies demonstrated that ATRA enhanced
the self-renewal of serially transplantable HSCs [27]. These
eﬀects of ATRA were restricted to a relatively primitive
cell population: in contrast to that observed for LKS+
cells, lineage-negative, c-kit-positive, Sca-1-negative cells
(LKS−), which exhibit CFU-S and CFC potential, but do
not contain HSCs [26], diﬀerentiated in response to ATRA
[24]. A summary of the eﬀects of ATRA on the production
of hematopoietic cell types from LKS+ are given in Figure 2.
The diﬀerent eﬀects of ATRA in hematopoiesis may be
due to the cell target, the RAR(s) activated in such cells,
or both. We and others have recently examined the expres-
sion of the diﬀerent RARs in puriﬁed populations of murine
hematopoietic cells and have found that the RARs are diﬀer-
entially expressed in diﬀerent cell types [27, 28]. LKS+ cells
(which contain HSCs and which have increased repopulat-
ing potential in response to ATRA) express RARα1, RARα2,
RARβ2, RARγ1, and RARγ2[ 27]. In contrast, LKS− cells
(which do not contain HSCs and which diﬀerentiate in re-
sponse to ATRA treatment) have similar RAR expression to
LKS+ but do not express RARβ2o rR A R γ1[ 27]. Additional
data using RAR knockout mice have revealed distinct roles
for the RARs in hematopoiesis.
1.6. Rolesofretinoicacidreceptorsinhematopoiesis
Previous studies have investigated the role of pharmacolog-
ical levels of ATRA in cultured hematopoietic cells. Such
studies do not, however, provide insight of the physiologi-
cal roles of the RARs in hematopoiesis. The importance of
RARα in granulopoiesis is demonstrated in APML patients,
whose leukemic cells have aberrant chromosomal translo-
cations that result in fusion of the RARα gene with other
genes, such as PML and PLZF [29] .T h e s ef u s i o ng e n ep r o d -
ucts ultimately result in a block in promyelocytic diﬀerenti-
ation, resulting in leukemia. Additional support for physio-
logical roles of RARs in hematopoiesis comes from studies
of mice either given a vitamin-A-deﬁcient diet [30]o rf e d
with a pan-RAR antagonist [31], who exhibit a dramatic in-
crease in myeloid cells in bone marrow, spleen, and periph-
eral blood. However, while this underscores the importance
of RARs in hematopoiesis, it does not discriminate between
roles of each of the diﬀerent RAR subtypes in hematopoiesis.
ATRA, the most widely used retinoid in therapeutic applica-
tions at present, activates all three RAR subtypes. Each of the
threeRARswerepreviouslyconsideredtohavesimilareﬀects
in diﬀerent organs, however recent data using mouse models
or RAR-speciﬁc ligands are now emerging to challenge and
even disprove this concept. Some studies on RAR knockouts
have also begun to delineate the diﬀerent roles of the RARs
in hematopoiesis, and are discussed below.
1.7. StudiesofHSCsinRAR-knockoutmice
Mice null for RARα,R A R β,o rR A R γ all survive birth, but
both RARα-a n dR A R γ knockout mice exhibit early lethality
[32–34]. Subsequent double null mice generated from these
RAR subtype null mice have more profound defects, and die
atthelatestby12hoursaftercaesareandeliveryatE18.5[35].
T h et r i p l en u l lm o u s eh a sn o tb e e nr e p o r t e dt od a t e .
PreviousreportsonhematopoiesisinRARnullmicehave
been two separate studies on granulocyte development in
RARα1a n df u l lR A R α knockouts. Both demonstrated that
RARα is not an important physiological regulator of gran-
ulocytes [28, 36]. Mice lacking both RARα1a n dR A R γ did
exhibit a block in in vitro terminal diﬀerentiation into gran-
ulocytes, but this was not observed in vivo, suggesting that
in vivo compensatory mechanisms in these double null mice
restore normal granulopoiesis [28].
Both RARα and RARγ are the most widely expressed in
hematopoiesis, including HSCs, hence we have investigated
the HSC content in 8-week-old RARα and RARγ null mice.
The RARα null mice had normal HSC content, as assessed by
limiting dilution analysis [27]. In contrast, whole bone mar-
row obtained from RARγ null mice had a 3.3-fold reduction
in the number of long-term repopulating HSCs in primary
transplant recipients compared to that of their wild-type lit-
termates [27]. Interestingly, bone marrow from RARγ het-
erozygous mice had 2-fold fewer HSCs than the wild-type4 PPAR Research
littermates,furtherhighlightingtheimportanceofRARγ sig-
nalling in the regulation of HSCs [27]. The reduced num-
bers of HSCs observed in RARγ null bone marrow was ac-
companiedbyincreasednumbersofmorematureprogenitor
cells (CFU-S and CFCs), suggesting that RARγ is critical for
maintaining a balance between HSC self-renewal and diﬀer-
entiation [27].
The response of enriched populations of HSCs (LKS+)
obtained from RAR mutants to ATRA treatment was also
monitored in ex vivo cultures. HSCs obtained from RARα
null mice retained a normal response to ATRA treatment,
as measured by prolonged and enhanced cell proliferation
and their ability to reconstitute mice after 14 days of ex vivo
culture [27]. In contrast, ATRA-treated LKS+ isolated from
RARγ null mice had markedly impaired proliferation and
did not reconstitute mice after 14 days of culture [27]. Col-
lectively, these studies demonstrate that ATRA-induced HSC
self-renewal requires RARγ signalling.
RARγ has therefore been identiﬁed as being a key regula-
tor of HSC self-renewal: activation of RARγ enhances self-
renewal, whereas inactivation of RARγ enhances HSC dif-
ferentiation, resulting in increased numbers of more mature
progenitor cells.
The recent generation of RAR-speciﬁc ligands [37]h a s
made future studies of the eﬀects of gain of function of
diﬀerent RARs on hematopoietic cells possible, and will
likely lead to further therapeutic applications for retinoids in
hematopoiesis.
1.8. Regulatorsofretinoidsignaling:aldehyde
dehydrogenasefamily
Little is known about the regulators of RARs in organogen-
esis. One major way of regulating activity of the RARs is by
altering the availability of the biologically active retinoic acid
ligands. A series of sequential enzymes with diﬀerent speci-
ﬁcities regulate the production of retinoic acid from retinol
[7].TheimportantenzymesinvolvedintheNAD-dependent
oxidation of the aldehyde forms of vitamin A into ATRA and
9-cis retinoic acid are those of the aldehyde dehydrogenase
(ALDH) family.
LikeRARs,theALDHsarehighlyconservedamongstver-
t e b r a t e s .T h e r ea r en u m e r o u sm e m b e r so ft h i sf a m i l y ,n o t
all of which can use retinoids as substrates. The cytosolic
class 1 enzymes, retinaldehyde dehydrogenase 1 (RALDH1),
RALDH2, and RALDH3, are the ALDH forms important for
the conversion of retinal into retinoic acid forms [7]. All
three enzymes are expressed diﬀerentially in embryogenesis
and throughout later mouse organogenesis [38].
RALDH1 (also known as ALDH1, ALDH1A1, RalDH1,
and Ahd2) is expressed in both embryonic and adult tis-
sues and is capable of converting both all-trans retinal and
9-cisretinalintotheirrespectivecarboxylicacidforms,hence
providing ligands for both the RARs and RXRs [7]. Raldh1
knockoutmiceareviable,withnoapparentdefectsingrowth
or survival [39]. RALDH2 (also known as ALDH1A2) is
more important embryonically, and Raldh2 knockout mice
die by E10.5, exhibiting multiple defects and a block in em-
bryonic retinoic acid synthesis [40]. Interestingly, this lethal
Table 1:ExpressionofRARsandALDH1inmurineHSCsandpro-
genitor cells.Positiveexpressionisindicatedby(+)andnegative ex-
pression by (−). Summary of data is obtained from references [27]
and [44].
Hematopoietic cell population
HSCs Progenitors
RARα1+ +
RARα2+ +
RARβ2+ −
RARγ1+ −
RARγ2+ +
ALDH1 + −
phenotype can almost be completely overcome by mater-
nal retinoic acid administration, demonstrating that the de-
fects in these mice are predominantly due to lack of retinoic
acid. RALDH3 (also known as ALDH1A3 and ALDH6) is
expressed in the ventral retina in the developing eye, olfac-
tory regions, and other organs [38, 41]. Raldh3 knockout
mice are born, but die from respiratory distress within 10
hours of birth [42]. To date there have been no reports on
hematopoiesis in any of the Raldh mutants.
A series of recent reports have shown that both murine
and human primitive HSCs and progenitors are contained
within the lineage-negative, ALDH high fraction, and can be
isolated based on ALDH activity [43–47]. In contrast, the
population of murine hematopoietic cells lacking ALDH1
expression did not contain HSCs [44]. These data therefore
notonlyreinforcetheimportanceofRARsignallinginHSCs,
asshowninourrecentstudies,butalsoprovideevidencethat
HSCs themselves are capable of generating ATRA and 9-cis
retinoic acid from retinal. A summary of the expression of
RARs and ALDH1 in murine HSCs and progenitor cells is
given in Table 1.
One study to date has reported that inhibiting ALDH1 in
human hematopoietic stem/progenitor cells in vitro induces
their expansion and prevents their diﬀerentiation [48]. Fur-
ther studies of the roles of the aldehyde dehydrogenases in
the regulation of HSCs are therefore of interest.
1.9. TherapeuticapplicationsofretinoidsforHSCs
Given that the retinoid pathway is highly conserved between
humanandmouse,itisnowofinteresttodeterminewhether
ATRA has the same eﬀects on human HSCs. Some obsta-
cles to these translational studies are that (1) the popu-
lation enriched for human HSCs is much more heteroge-
neous than the one that can be obtained for murine HSCs,
which presents potential problems given the pleiotropic ef-
fects of ATRA and (2) the NOD/SCID mouse repopulat-
ing assay, which to date is the best small animal model for
in vivo transplantation studies of human HSCs, may not
be reﬂecting true HSC activity of the cell population [49].
Nevertheless, a recent report demonstrated that ATRA could
support the expansion of SCID-repopulating cells (SRC),
human hematopoietic cells that are capable of repopulat-
ing NOD/SCID mice [50]. These eﬀects of ATRA on humanLouise E. Purton 5
hematopoietic stem/progenitor cells relied on the presence
of a stromal feeder layer, but did not require contact between
the stromal cells and HSPCs [50]. It is therefore likely that
ATRA induced the secretion of substances from the stromal
cells that were capable of expanding HSPC. The potential use
ofretinoidstoexpandhumanHSCsfortherapeuticpurposes
therefore warrants further investigation: in particular, given
its profound roles in murine HSCs, it is of interest to deter-
mine the eﬀects of speciﬁcally activating RARγ in these cells.
2. CONCLUSION
It is becoming apparent that the roles of retinoids and their
receptors in hematopoiesis are complex, having pleiotropic
eﬀects depending on the hematopoietic target cell. In con-
trast to its potent diﬀerentiation-inducing eﬀects on granu-
locyte progenitor cells, ATRA enhanced the self-renewal of
HSCs. These diﬀerent eﬀects are likely due to the eﬀects of
the distinct RARs in hematopoiesis. RARα has a clear role in
enhancing granulocyte maturation, as demonstrated by both
its involvement in APML [29] and also the potent eﬀects of
an RARα-speciﬁc ligand on granulocyte diﬀerentiation [22].
We also recently reported that an RARα-speciﬁc ligand en-
hanced the mobilization of murine hematopoietic stem and
progenitor cells into the peripheral blood for transplantation
purposes via increasing the numbers of immature granulo-
cyte progenitors in vivo [51]. Interestingly, these eﬀects were
not seen when ATRA was used in place of the RARα-speciﬁc
ligand, perhaps due to contrasting eﬀects obtained by ac-
tivating all three diﬀerent RARs concurrently, a possibility
that further adds to the complexity of the eﬀects of retinoids
in hematopoiesis. In contrast, RARγ is a major regulator of
HSC self-renewal: gain of function of RARγ enhances HSC
self-renewal, whereas loss of function of RARγ promotes dif-
ferentiation of HSCs [27]. These distinct eﬀects of the RARs
in hematopoiesis suggests that, in the future, therapeutically
targeting theRARsviaRAR-speciﬁcligandsmayhaveamore
profound eﬀect on the target cell than by using the pan-RAR
agonist ATRA. Such studies will also permit further delin-
eation of the roles of the RARs in HSC biology.
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